The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
ASCO-SITC Clinical Immuno-Oncology Symposium: abstract submission deadline 3rd October
The next ASCO-SITC Clinical Immuno-Oncology Symposium will take place in San Francisco, CA, USA from 25th–27th January 2018. Abstract submission is due to close on Tuesday 3rd October 2017, 11:59 pm EDT.
The deadline for Late-Breaking Abstract (LBA) submissions is Tuesday 21st November 2017 at 12:00 pm (noon) EDT; however, authors must submit a shell/placeholder abstract by October 3rd to be considered for LBA submission.
The symposium is described as “a three-day meeting focused on clinical and translational research in immune-oncology and the implications for clinical care” and aims to “address the high-level need for clinical education in a field where all aspects of care are fundamentally different from traditional therapies.” The program will offer insights into the use of immunotherapy in hematologic malignancies, as well as in melanoma, lung cancer, and solid tumors through a varied number of sessions including Keynote Lectures, early morning “Immunology 101” talks, “Networking Roundtable” opportunities, and “Evening Highlights” sessions.
Subcategories within the Hematologic Malignancies category include: biomarkers and inflammatory signatures, cell therapies, humoral immunity for diagnosis and therapy, immune checkpoints and stimulatory receptors, and modulating innate immunity.
For more information on abstract submission guidelines, visit: http://immunosym.org/abstracts/abstract-submission-guidelines
References